aprepitant capsules — CareFirst (Caremark)
Prevention of nausea and vomiting associated with highly or moderately emetogenic cancer chemotherapy
Initial criteria
- Requested drug is being prescribed for prevention of nausea and vomiting associated with highly or moderately emetogenic cancer chemotherapy
- The request is NOT for Varubi (rolapitant)
- The requested drug will be used in combination with other antiemetic agents
Approval duration
6 months